OSDDMalaria:OSDD Malaria Meeting Sydney 2012: Difference between revisions
Matthew Todd (talk | contribs) |
Matthew Todd (talk | contribs) (→Attending: added adams) |
||
| Line 50: | Line 50: | ||
* [https://twitter.com/#!/neilfws Neil Saunders], Bioinformatician, [http://www.csiro.au/org/CMIS CSIRO] | * [https://twitter.com/#!/neilfws Neil Saunders], Bioinformatician, [http://www.csiro.au/org/CMIS CSIRO] | ||
* [http://www.policycures.org/staff.html Mary Moran], Policy Cures | * [http://www.policycures.org/staff.html Mary Moran], Policy Cures | ||
* [http://www.linkedin.com/in/nicoadams Nico Adams], CSIRO | |||
===Invited=== | ===Invited=== | ||
Revision as of 01:34, 4 February 2012
Open Source Drug Discovery for Malaria - February 24th 2012
There will be a one-day meeting on Open Source Drug Discovery for Malaria at The University of Sydney, February 2012.
Location Information
The meeting will take place on the main Camperdown campus of The University of Sydney.
Schedule
9 a.m. start Welcome by Mat Todd and opening remarks by Mary O'Kane, NSW Chief Scientist.
Morning session 1: What is the current status of drug discovery and development (with some focus on malaria)? Sessions to be led by Mary Moran and Luigi Palombi.
Coffee
Morning session 2: What is the scientific and economic case for open source drug discovery? Mat Todd and his team will describe what open science is, and how it can be done.
Lunch
Afternoon session 1: What are the most significant types of drugs needed for the treatment of malaria? Paul Willis will lead a survey of current treatments.
Afternoon session 2: Which compounds should we pursue? Who should do it? How?
5 p.m. Drinks and dinner
Sessions will broadly address these questions:
General:
- How is it best to share chemical and biological data in an open project?
- What technical barriers prevent open science?
- Which licence governs an open source drug discovery project?
- What psychological/professional barriers are there to open science?
- Is there a danger that open source drug discovery can be hijacked by people taking all the data and patenting them?
- Who might participate?
- Who will fund later stages such as clinical trials?
- Who will manufacture open drugs?
Malaria-specific:
- Is the GSK arylpyrrole set the best set of compounds to start with?
- What other compounds are promising starting point? Who might want to work on those compounds?
- For hit-to-lead, what data are typically needed, and from which assays? What criteria do we apply to compounds as they progress through such assays?
To suggest questions/sessions of interest, please modify this page directly (getting an OWW account is very easy) or contact Mat Todd.
Attending
- Mat Todd, University of Sydney
- Mary O'Kane, NSW Chief Scientist
- Luigi Palombi, Centre for Governance of Knowledge and Development, ANU, Canberra
- Paul Willis, MMV, Geneva
- Saman Habib, CDRI, Lucknow, India
- Stuart Ralph, Bio21, University of Melbourne
- Paul Ylioja, University of Sydney
- Murray Robertson, University of Sydney
- Neil Saunders, Bioinformatician, CSIRO
- Mary Moran, Policy Cures
- Nico Adams, CSIRO
Invited
- Alastair Robertson, CSIRO
- Richard Head, CSIRO
- Nick Hunt, The University of Sydney
- Richard Jefferson, CAMBIA
- Alan Cowman, WEHI
- Susan Charman
- Michelle Gatton
- Hazel Moir
Potential Invitees
Possibly interesting list maintained here
